Viridian Therapeutics is a biopharmaceutical company discovering and developing medicines for serious autoimmune and rare diseases, with a focus on thyroid eye disease, related immune disorders, and Graves' disease. The company's lead programs are monoclonal antibodies targeting IGF-1R that offer improved efficacy and convenience over existing treatments, along with a portfolio of FcRn inhibitors designed for subcutaneous self-administration across multiple autoimmune indications. Viridian generates revenue through clinical development, regulatory approvals, and commercialization of its own medicines while retaining worldwide rights (with selected regional partnerships), supplemented by licensing and collaboration agreements that provide upfront payments, milestone revenues, and royalties on future sales.